Logo image of APLM

APOLLOMICS INC (APLM) Stock Fundamental Analysis

NASDAQ:APLM - Nasdaq - KYG0411D1236 - Common Stock - Currency: USD

6.634  +1.29 (+24.23%)

Fundamental Rating

1

Overall APLM gets a fundamental rating of 1 out of 10. We evaluated APLM against 558 industry peers in the Biotechnology industry. APLM has a bad profitability rating. Also its financial health evaluation is rather negative. APLM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APLM had negative earnings in the past year.
APLM had a negative operating cash flow in the past year.
APLM Yearly Net Income VS EBIT VS OCF VS FCFAPLM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

The Return On Assets of APLM (-311.63%) is worse than 93.55% of its industry peers.
Looking at the Return On Equity, with a value of -418.59%, APLM is doing worse than 76.70% of the companies in the same industry.
Industry RankSector Rank
ROA -311.63%
ROE -418.59%
ROIC N/A
ROA(3y)-104.14%
ROA(5y)N/A
ROE(3y)-139.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APLM Yearly ROA, ROE, ROICAPLM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

APLM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APLM Yearly Profit, Operating, Gross MarginsAPLM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

APLM has more shares outstanding than it did 1 year ago.
APLM has a worse debt/assets ratio than last year.
APLM Yearly Shares OutstandingAPLM Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M 80M
APLM Yearly Total Debt VS Total AssetsAPLM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -25.42, we must say that APLM is in the distress zone and has some risk of bankruptcy.
APLM's Altman-Z score of -25.42 is on the low side compared to the rest of the industry. APLM is outperformed by 88.17% of its industry peers.
APLM has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
APLM has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -25.42
ROIC/WACCN/A
WACCN/A
APLM Yearly LT Debt VS Equity VS FCFAPLM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.95 indicates that APLM has no problem at all paying its short term obligations.
APLM has a worse Current ratio (2.95) than 66.13% of its industry peers.
A Quick Ratio of 2.95 indicates that APLM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.95, APLM is not doing good in the industry: 64.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95
APLM Yearly Current Assets VS Current LiabilitesAPLM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

APLM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3757.18%.
EPS 1Y (TTM)-3757.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

APLM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.80% yearly.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y99.53%
EPS Next 2Y41.2%
EPS Next 3Y25.8%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-23.3%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

APLM Yearly Revenue VS EstimatesAPLM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 500K 1M 1.5M
APLM Yearly EPS VS EstimatesAPLM Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APLM. In the last year negative earnings were reported.
Also next year APLM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLM Price Earnings VS Forward Price EarningsAPLM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLM Per share dataAPLM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

APLM's earnings are expected to grow with 25.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.2%
EPS Next 3Y25.8%

More info and screens

0

5. Dividend

5.1 Amount

APLM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APOLLOMICS INC

NASDAQ:APLM (6/24/2025, 4:30:00 PM)

6.634

+1.29 (+24.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2024-03-28/bmo
Earnings (Next)N/A N/A
Inst Owners0.22%
Inst Owner ChangeN/A
Ins Owners20.62%
Ins Owner ChangeN/A
Market Cap7.30M
Analysts82.86
Price TargetN/A
Short Float %1.57%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.28
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-39.29
FCFYN/A
OCF(TTM)-39.28
OCFYN/A
SpS0
BVpS37.49
TBVpS24.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -311.63%
ROE -418.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-104.14%
ROA(5y)N/A
ROE(3y)-139.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z -25.42
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3757.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y99.53%
EPS Next 2Y41.2%
EPS Next 3Y25.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-23.3%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-9748.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.82%
EBIT Next 3Y-32.4%
EBIT Next 5YN/A
FCF growth 1Y-4810.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4810.11%
OCF growth 3YN/A
OCF growth 5YN/A